Anixa Biosciences (NASDAQ:ANIX) versus Dermata Therapeutics (NASDAQ:DRMA) Financial Survey

Anixa Biosciences (NASDAQ:ANIX) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Profitability

This table compares Anixa Biosciences and Dermata Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Dermata Therapeutics	N/A	-127.91%	-105.05%

Volatility & Risk

Anixa Biosciences has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.

Institutional & Insider Ownership

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by insiders. Comparatively, 21.9% of Dermata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations for Anixa Biosciences and Dermata Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1	0	3	1	2.80
Dermata Therapeutics	1	0	1	0	2.00

Anixa Biosciences currently has a consensus target price of $8.50, suggesting a potential upside of 148.54%. Dermata Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 754.70%. Given Dermata Therapeutics’ higher possible upside, analysts clearly believe Dermata Therapeutics is more favorable than Anixa Biosciences.

Earnings & Valuation

This table compares Anixa Biosciences and Dermata Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210,000.00	554.04	-$10.93 million	($0.31)	-11.03
Dermata Therapeutics	N/A	N/A	-$7.56 million	($5.31)	-0.22

Dermata Therapeutics has lower revenue, but higher earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Anixa Biosciences beats Dermata Therapeutics on 9 of the 13 factors compared between the two stocks.

About Anixa Biosciences

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

About Dermata Therapeutics

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.